<?xml version="1.0" encoding="UTF-8"?>
<root>
    <author>ENA</author>
    <category>Sectors</category>
    <date>2024-11-25 17:40:09</date>
    <fulldesc>&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;&lt;strong&gt;New Delhi, Nov 25 (KNN)&lt;/strong&gt; Major pharmaceutical companies in India reported a robust 10 per cent year-on-year (YoY) growth in the second quarter of FY25, driven by strong performances in North America and the domestic market, according to a report by Axis Securities.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;This growth is largely attributed to the continued expansion of chronic therapies, which grew by 9 per cent, while the Indian Pharmaceutical Market (IPM) experienced an overall 8 per cent YoY increase.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;The report highlights that the pharmaceutical sector under Axis Securities coverage recorded a 10.2 per cent YoY growth and a 1.7 per cent quarter-on-quarter (QoQ) increase.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;North America, a key export market, saw a solid 10.8 per cent YoY growth, while the domestic market grew by 9.8 per cent.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Despite challenges in acute therapies, which experienced only a modest 4 per cent growth due to weaker seasonal demand, the overall pharmaceutical outlook remains positive.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Axis Securities anticipates significant future potential, particularly in emerging segments such as biosimilars, GLP-1, and peptides, all of which are focused on treating conditions like diabetes.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;These therapies are expected to bolster growth in the coming years, with companies focusing heavily on chronic treatment portfolios expected to outperform the broader market.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;In the healthcare sector, Q2 FY25 also showed impressive growth, with top-line revenue increasing by 17.6 per cent YoY and 10.4 per cent QoQ.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Hospital occupancy rates, which rose by 340 basis points (bps) YoY and 470 bps QoQ, were a key driver of this performance.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;The hospital segment saw insurance payers contribute 33 per cent of total revenue, marking a significant 23 per cent YoY and 12 per cent QoQ growth.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;However, the report notes that insurance penetration remains low in India, offering opportunities for expansion as awareness and purchasing power increase.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;High-growth therapies, such as cancer and cardiac care, continued to drive double-digit growth in the hospital sector.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;With rising occupancy rates and improved revenue per bed, the outlook for sustained growth in both the pharmaceutical and healthcare sectors remains optimistic.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;&lt;span style=&quot;font-size:14px&quot;&gt;(KNN Bureau)&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&#13;
</fulldesc>
    <id>40033</id>
    <link>https://knnindia.co.in/news/newsdetails/sectors/pharmaceutical-and-healthcare-sectors-report-strong-growth-in-q2-fy25</link>
    <pubDate>2024-11-25 17:40:09</pubDate>
    <source>knnindia.co.in</source>
    <title>Pharmaceutical and Healthcare Sectors Report Strong Growth in Q2 FY25</title>
</root>
